China‑based Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347) announced that it and its subsidiary Jiaxing Xinge Medical Consulting Co., Ltd. have entered into a share‑transfer agreement with Frontage Laboratories (Shanghai) Co., Ltd. to sell the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd. for a total consideration of RMB 270 million.
Deal Overview
- Parties Involved
- Seller: Tigermed Consulting Co., Ltd. and Jiaxing Xinge Medical Consulting Co., Ltd.
- Buyer: Frontage Laboratories (Shanghai) Co., Ltd.
- Target: Teddy Clinical Research Laboratory (Shanghai) Ltd., a wholly‑owned subsidiary of Tigermed.
- Consideration: RMB 270 million in cash and related closing adjustments.
Transaction Details
- Effective Date: 10 October 2025 (U.S. Time).
- Post‑Closure Status: Teddy Clinical remains a subsidiary of Tigermed; the transaction is a share‑only transfer, not a divestiture of operations.
- Regulatory Filings: All necessary filings with the China Securities Regulatory Commission and the Shanghai Stock Exchange have been completed.
Strategic Rationale
- Resource Optimization – The sale frees up capital that Tigermed can redeploy to high‑growth segments of its clinical‑trial portfolio.
- Operational Efficiency – By consolidating internal resources, Tigermed aims to streamline its service offerings, reduce overhead, and accelerate time‑to‑market for new clinical solutions.
- Synergy Realization – Frontage Laboratories will benefit from TigerMed’s established client base and infrastructure, while Tigermed retains core assets to support its long‑term R&D strategy.
Next Steps
- Integration – Tigermed will coordinate with Frontage Laboratories to ensure a seamless transition of client relationships and data management.
- Capital Allocation – Proceeds from the transaction will be earmarked for expansion of Tigermed’s analytical services and digital health platforms.
- Stakeholder Communication – A joint press release and investor update will be issued within the next 48 hours to inform shareholders and regulatory authorities.-Fineline Info & Tech
